Regulation 5 Exception for medicines indicated for the treatment of persons aged under 18
This regulation applies to the sale of a nicotine inhaling product which—
is an authorised medicinal product; and
is indicated for the treatment of persons of the age of the person to whom the product is sold.
For the purposes of this regulation—
a product is indicated for the treatment of persons of a particular age if it is described as such in the summary of the product characteristics for the product in accordance with paragraph 27 of Schedule 8 to the Human Medicines Regulations 2012 (summary of the product characteristics) F1...;
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
a medicinal product is “authorised” if one of the following is in force for the product—
a F3UK marketing authorisation; or
a parallel import licence.
Annotations
Textual amendments
- F1
Words in reg. 5(2)(a) omitted (31.12.2020) by virtue of The Tobacco Products and Nicotine Inhaling Products (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/41), regs. 1, 5(2)(a); 2020 c. 1, Sch. 5 para. 1(1)
- F2
Reg. 5(2)(b) omitted (31.12.2020) by virtue of The Tobacco Products and Nicotine Inhaling Products (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/41), regs. 1, 5(2)(b); 2020 c. 1, Sch. 5 para. 1(1)
- F3
Word in reg. 5(2)(c)(i) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 13(3); 2020 c. 1, Sch. 5 para. 1(1)